Correspondence kettenmann@mdc-berlin.de (H.K.), seija.lehnardt@charite. de (S.L.) In Brief Buonfiglioli et al. elucidate the role of let-7 miRNAs acting as Toll-like receptor (TLR) ligands in the brain. Select let-7 miRNAs function as signaling molecules to modulate diverse microglial functions and glioma growth through TLR7. These data establish let-7 miRNAs as TLR7 signaling activators of microglia in health and glioma.
INTRODUCTION
MicroRNAs (miRNAs) are short, non-coding single-stranded RNA (ssRNA) molecules, shown to posttranscriptionally regulate gene expression (Bartel, 2004) . The lethal-7 (let-7) miRNA family, the first miRNA family identified in humans , includes nine mature members (let-7a-let-7i and miR-98) . let-7 miRNAs, which are abundantly expressed in the brain and exhibit high cross-species sequence conservation (Pena et al., 2009; Reinhart et al., 2000) , have been shown to regulate cell differentiation and brain tumor growth (Gilles and Slack, 2018; Lee et al., 2016) . miRNAs are also present in the extracellular space, derived either from dying cells or actively released within vesicles (e.g., exosomes), where they function as signaling molecules (Feng et al., 2017; Lehmann et al., 2012a) . Some miRNAs can serve as ligands for Toll-like receptors (TLRs) (Fabbri et al., 2012; Feng et al., 2017; Lehmann et al., 2012a) . TLRs belong to a family of pattern recognition receptors, which recognize pathogenassociated molecules, such as bacterial and viral components, and damage-associated molecules derived from necrotic cells and tumor tissue (Tang et al., 2012) . Upon activation, TLRs signal through a complex array of effector proteins resulting in inflammation (Kawai and Akira, 2006) . Importantly, there is sequence specificity to miRNA engagement of TLRs, in that the GUUGUGU motif, found in let-7b, is required for TLR7 recognition of ssRNA40, a nucleotide derived from HIV (Heil et al., 2004) .
Microglia respond to brain pathological states by migrating toward the lesion site, releasing inflammatory molecules, engulfing cell debris (Napoli and Neumann, 2009) , and presenting diseaseassociated antigen, thereby contributing to CNS disease pathobiology (Wlodarczyk et al., 2014) . Some of these responses are mediated by TLRs, such as TLR7, which detects ssRNA (Diebold et al., 2004; Heil et al., 2004) and controls microglial chemotaxis (Ifuku et al., 2016) . Additional TLRs regulate microglial motility (TLR2; Ifuku et al., 2016) and phagocytosis of Ab amyloid in Alzheimer's disease (TLR4; Rajbhandari et al., 2014) . In the setting of glioblastoma (GBM), the most aggressive brain tumor in adults with survival of less than 15 months from diagnosis (Louis et al., 2016; Stupp et al., 2005) , TLR2 and TLR4 control the interaction between glioma cells and microglia, thereby promoting tumor expansion (Dzaye et al., 2016; Hu et al., 2015; Vinnakota et al., 2013) . Glioma-associated microglia and invading peripheral macrophages constitute up to 30% of the tumor tissue, adopting a tumor-supportive phenotype (Hambardzumyan et al., 2016) .
Here, we systematically analyzed the different members of the let-7 miRNA family to determine which of these molecules function as microglial TLR signaling molecules. We found that a defined subset of the let-7 miRNA family, characterized by a specific nucleotide sequence, activates TLR7 and modulates microglial release of inflammatory cytokines, migration, and antigen presentation. This selectivity operates in the setting of GBM, in which select let-7 miRNAs inhibit tumor growth via microglial TLR7 signaling. Our data establish that let-7 miRNA dictates microglial function through TLR7 signaling, which is important for physiological and pathological processes in the CNS.
RESULTS AND DISCUSSION
Select Members of the let-7 miRNA Family Activate Microglia via TLR7 Signaling Microglia are the resident immune cells of the CNS, where they function as sensors of changes in their environment caused by invading pathogens and host-derived factors. Following activation, microglia migrate to the lesion site and secrete cytokines and chemokines (Kettenmann et al., 2011) . These responses are regulated in part by TLRs. Consistent with a central role for TLRs in brain homeostasis, miRNAs serve as TLR signaling activators (Fabbri et al., 2012; Feng et al., 2017; He et al., 2013; Lehmann et al., 2012a) . miRNA dysregulation is linked to inflammatory and immune responses, which modulate cancer initiation and progression (Gilles and Slack, 2018) . On the basis of sequence similarity to known TLR7 ligands, such as the oligoribonucleotide ssRNA40 derived from HIV, their abundant expression in the CNS, and their key role in immune responses in pathology including cancer, we focused on the let-7 miRNA family members as potential signaling activators of microglia in health and in the setting of GBM. To this end, first we sought to systematically investigate the potential of different let-7 miRNA family members (Table S1 ) to activate TLR7 in microglia. Cultured microglia from neonatal wild-type (WT) mice were incubated for 9, 24, and 30 h with synthetic oligoribonucleotides derived from the let-7 miRNA family at different concentrations (1, 5, and 10 mg/mL), and analyzed for TNF-a release using ELISA. Lipopolysaccharide (LPS) and loxoribine (LOX) served as positive controls for TLR4 and TLR7 activation, induced TNF-a release from microglia time-and dose-dependently ( Figure 1A) . There was increased TNF-a release after 24 h relative to 9 h, while after 30 h, at 5 mg/mL, there was no further increase. TNF-a release in response to 5 mg/mL let-7 miRNA was higher compared with 1 mg/mL, but not much different at 10 mg/mL after 24 h. let-7 miRNA-induced responses were sequence specific, as control oligoribonucleotides with a mutant sequence did not induce TNF-a release. In contrast to the responses triggered by the let-7 miRNAs above, TNF-a induced by let-7d, let-7i, and miR-98 was only slightly increased relative to control (Figure 1A) . Using biotinylated let-7b, we confirmed that extracellularly delivered let-7 miRNA enters microglia ( Figure 1B) . To determine whether TLR7 is required for microglial activation by let-7 miRNAs, microglia from neonatal Tlr7 À/À mice were investigated. In contrast to WT microglia, TLR7-deficient microglia failed to release amounts of TNF-a in response to stimulation with any of the members of the let-7 miRNA family at 5 mg/mL within 24 h ( Figure 1C ). As expected, stimulation with LOX was abolished in Tlr7 À/À mice, while LPS-and Pam2CSK4 (ligand for TLR2)-induced responses were unaffected. Stimulation of Tlr7 À/À microglia with different doses (1, 5, or 10 mg/mL) of any of the let-7 miRNAs within 24 h or with 5 mg/mL let-7 miRNA over different time periods (9, 24, or 30 h) did not result in significant TNF-a production compared with control ( Figure S1 ). To exclude the possibility that the effects were due to contamination with TLR4 and/or TLR2 ligands, such as LPS or lipoproteins, we tested microglia from Tlr2 À/À and Tlr4 À/À mice ( Figure 1C ). TLR2and TLR4-deficient microglia released TNF-a in response to the same let-7 family members that activated WT microglia. TNF-a release induced by LPS in TLR4-deficient microglia, and by the TLR2 agonist Pam2CSK4 in TLR2-deficient microglia, was abolished.
To test whether let-7-mediated activation of microglia depends on their developmental stage or the isolation procedure, we compared TNF-a release triggered by let-7 family members in postnatal microglia cultures to microglia from adult tissue and freshly isolated adult microglia. Adult microglia were isolated from 8-week-old mice and were grown in vitro for 3 weeks. Freshly isolated microglia were obtained from 12-week-old mice via fluorescence-activated cell sorting (FACS) and were seeded overnight before stimulation. Cells were stimulated with the different let-7 family members and analyzed using ELISA ( Figure 2 ). Adult microglia and freshly isolated adult microglia released TNF-a in response to let-7b, let-7c, let-7e, let-7f, and let-7g . Compared with neonatal microglia, these responses were smaller in magnitude. As observed in neonatal microglia, adult microglia and freshly isolated adult microglia exhibited little TNF-a release in response to let-7a, let-7d, let-7i, or miR-98 stimulation (Figure 2 ). These microglial responses were sequence specific, as control oligoribonucleotides with a mutant sequence did not induce TNF-a release. To confirm let-7 miRNAs as signaling activators of immune cells, not only in the CNS but also in the periphery, we analyzed bone marrow-derived macrophages using the same experimental protocol. Monocytes were isolated from bone marrows of 8-week-old mice and differentiated into macrophages for 6 days. We observed a sequence-specific release of TNF-a from bone marrow-derived macrophages stimulated with let-7b, let-7e, let-7f, and let-7g ( Figure 2) . In contrast to microglia, TNF-a release at 24 and 30 h was not different from TNF-a release at 9 h ( Figure S2 ). let-7d, let-7i, and miR-98 stimulation did not result in TNF-a production in macrophages ( Figure 2 ). Taken together, extracellularly delivered let-7 miRNAs differentially induce microglial activation through TLR7. The ability of microglia to respond to let-7 miRNAs does not depend on their developmental stage, implying a functional role for extracellular let-7 miRNAs in CNS diseases occurring at all ages. The precise local concentrations of extracellularly functional let-7b (or other members of the let-7 miRNA family) in the brain parenchyma at the site of injury/pathology in vivo are not known. For this reason, the concentrations of let-7 miRNAs used in the present study were based on our previous work on ssRNA-mediated neurodegeneration, in which we found that injured neurons, and potentially other CNS cells, release let-7b into the extracellular space (Lehmann et al., 2012a (Lehmann et al., , 2012b . Future work will be required to determine pathophysiological concentrations of let-7 miRNAs in the brain.
Select let-7 miRNAs Induce a Specific Pattern of Inflammatory Molecules Released from Microglia through TLR7 Although TNF-a is a well-studied cytokine released in response to TLR activation, additional cytokines and chemokines are also released from microglia. To determine the specific inflammatory response pattern induced by let-7 miRNAs via TLR7, we used a multiplex immunoassay and analyzed the supernatants from neonatal WT and Tlr7 À/À microglia incubated with 5 mg/mL of the respective let-7 miRNA family member after 24 h. Mutant oligoribonucleotide and the TLR7 ligand LOX served as controls. IL-6, IL-10, IL-1b, GRO-a, MIP-2, and (A) Primary neonatal microglia from wild-type (WT) mice were stimulated with 5 mg/mL of let-7a-let-7i or miR-98 oligoribonucleotides for 9, 24, or 30 h (top) or with 1, 5, or 10 mg/mL of let-7a-let-7i or miR-98 oligoribonucleotides for 24 h (bottom). TNF-a release was determined using ELISA. Lipopolysaccharide (LPS; 100 ng/mL) and loxoribine (LOX; 1 mM) were used as known TLR4 and TLR7 activators, respectively, while mutant oligoribonucleotide (mut. oligo; 5 mg/mL) and LyoVec served as negative controls. n = 5. (B) Representative images of cultured neonatal microglia from WT mice incubated with 5 mg/mL biotinylated let-7b for 6 h. Cells were stained with Iba1 antibody and DAPI. Unstimulated microglia served as control. Scale bar, 30 mm. (C) Primary neonatal microglia from WT, Tlr7 À/À , Tlr2 À/À , and Tlr4 À/À mice were stimulated with 5 mg/mL let-7a-let-7i and miR-98 for 24 h. TNF-a release was determined using ELISA. LPS (100 ng/mL), LOX (1 mM), and Pam2CSK4 (100 ng/mL) were used as positive controls for TLR4, TLR7, and TLR2 activation, respectively, while incubation with mut. oligo (5 mg/mL) and LyoVec served as negative controls. n = 5. Data are represented as mean ± SEM. *p < 0.05, **p < 0.01, and ***p < 0.001 versus control (Kruskal-Wallis followed by Dunn's post hoc test). See also Figure S1 and Table S1 . RANTES were released from WT microglia after let-7a, let-7b, let-7c, let-7e, let-7f, and let-7g stimulation in a sequence-dependent fashion, while incubation with let-7d, let-7i, or miR-98 did not result in much cytokine release ( Figure 3A ; Table S2 ). GM-CSF, IP-10, MCP-1, and MCP-3 were not increased after stimulation with any of the let-7 miRNAs tested ( Figure S3 ; Table S3 ). IL-6, IL-10, IL-1b, GRO-a, MIP-2, and RANTES induction required TLR7, as TLR7-deficient cells failed to respond to let-7 miRNA ( Figure 3A ). MIP-1a and MIP-1b were released from microglia in response to all tested let-7 miRNAs, but this response was not dependent on TLR7 ( Figure S3 ). In summary, selected extracellularly delivered let-7 miRNA family members induce a sequence-specific and TLR7-dependent inflammatory response with a distinct profile of cytokine release. Although Primary cultured neonatal, adult cultured microglia, freshly isolated microglia, and primary bone marrow-derived macrophages from adult WT mice were stimulated with 5 mg/mL let-7a-let-7i or miR-98 oligoribonucleotides, as indicated, for 24 h. TNF-a levels were determined using ELISA. LPS (100 ng/mL) and LOX (1 mM) were used as TLR4 and TLR7 ligands, respectively. Mut. oligo (5 mg/mL) and LyoVec served as negative controls. n = 4-6. Data are represented as mean ± SEM. *p < 0.05, **p < 0.01, and ***p < 0.001 versus control (Kruskal-Wallis followed by Dunn's post hoc test). See also Figure S2 . (A) Multiplex immunoassay was performed to characterize the inflammatory response in WT (top) and Tlr7 À/À (bottom) microglia in response to let-7b, let-7d, and let-7e using the supernatants collected for TNF-a analysis in Figure 1 . Data are shown in a heatmap representing cytokine release expressed in logarithmic of mean fluorescence intensity (MFI). LPS, LOX, and mut. oligo and LyoVec were used as positive and negative controls, respectively. n = 5. For p values yielded by Kruskal-Wallis test followed by Dunn's multiple comparison post hoc test, refer to Table S2 . (B) Primary neonatal microglia from WT and Tlr7 À/À mice were incubated with 5 mg/mL let-7b, let-7d, and let-7e for 24 h. MHC I, MHC II, and CD54 expression were analyzed using FACS. Marker expression is shown as mean fluorescent intensity (MFI) normalized to unstimulated control. LPS (100 ng/mL), LOX (1 mM), and IFN-g (100 ng/mL) served as positive controls. Mut. oligo (5 mg/mL) and LyoVec served as negative controls. n = 4-10. Data are represented as mean ± SEM. *p < 0.05, **p < 0.01, and ***p < 0.001 versus control (one-way ANOVA followed by Bonferroni post hoc test). See also Figures S3 and S4 and Table S3 . some of the inflammatory molecules, including TNF-a, IL-6, and IL-1b, have previously been reported as outputs of increased TLR7 signaling (Petes et al., 2017) and in the setting of glioma (Dzaye et al., 2016; Bowman et al., 2016; Zhu et al., 2012) , the pattern of cytokines and chemokines determined in our study reflects the specific let-7 miRNA family member used to stimulate microglia. Because let-7 miRNAs differ only slightly within their GU-rich sequence motifs (see below), these data explain how individual miRNAs serving as signaling molecules may modify CNS inflammation in a sequence-dependent manner. In addition, our findings raise the possibility that specific combinations of inflammatory molecules may uniquely affect brain disease pathogenesis. For example, select let-7 miRNA family members induce IL-6 release from microglia, which has been previously shown to promote the invasiveness of glioma cells (Zhang et al., 2012) .
let-7b and let-7e Modulate the Expression of Antigen-Presenting Markers via TLR7 Microglia act as antigen-presenting cells in the CNS, regulating innate and adaptive immune responses. Major histocompatibility complex (MHC) class I is expressed by all nucleated cells and is responsible for the activation of CD8 + T cells and natural killer cells, while MHC II is expressed by immune cells and activates CD4 + T cells. CD54 (ICAM-1) is also important for antigen presentation (Werner et al., 1998; Zuckerman et al., 1998) . Microglia from WT and Tlr7 À/À mice were analyzed using FACS for MHC I, MHC II, and CD54 expression following stimulation with 5 mg/mL let-7b and let-7e, which were observed to induce a potent cytokine response in microglia, and let-7d, which comparatively induced a weak cytokine response, for 24 h. LPS, loxoribine and IFN-g were used as positive controls for TLR4 and TLR7 activation, as well as general microglial activation, respectively ( Figure 3B ; for FACS gating strategy and histogram plots, see Figure S4 ). Treatment with let-7b and let-7e, but not let-7d, increased MHC I, but not MHC II, expression. CD54 expression was increased in response to let-7b and let-7e and to a lesser extent to let-7d in microglia. let-7-miRNA-induced upregulation of MHC I and CD54 expression required TLR7, as Tlr7 À/À microglia did not respond to the treatments ( Figure 3B ). In summary, select let-7 miRNAs affected the expression of specific molecules crucial for antigen presentation in the CNS. MHC I and CD54 expression was dependent on TLR7. Both molecules are important for the communication between innate and adaptive immune cells. Specifically, MHC I is recognized by cytotoxic T cells, triggering an immediate immune response against a non-self-antigen, and natural killer cells, which directly kill antigen-presenting cells, such as virus-infected or tumor cells. Whether MHC I and CD54 expression in microglia in response to let-7 miRNAs directly triggers T cell and natural killer cell activation remains unexplored at this stage and requires further investigation.
Select let-7 miRNAs Induce Chemotaxis, but Not Motility, in Microglia through TLR7 In response to brain injury or pathology, microglia migrate to the afflicted sites, where they phagocytose pathogens, apoptotic cells, and cellular debris. We have previously shown that chemotaxis is controlled by TLR7 in microglia (Ifuku et al., 2016) . As let-7 miRNAs were found to serve as signaling activators of TLR7 in microglia, thereby inducing an inflammatory response, we investigated the let-7 miRNAs' impact on microglial migration. To this end, microglia stimulated with let-7b, let-7e, and let-7d were analyzed using an agarose spot assay with a gradient to evaluate directed migration or without a gradient to test motility ( Figures 4A and 4B ). The let-7 miRNAs as well as mutant oligoribonucleotides were added either to the spot alone or into both the spot and the medium. Cells that entered the spot within 3 h were quantified. PBS was used as negative control. let-7b, let-7d, and let-7e, but also the mutant oligoribonucleotide, increased microglial chemotaxis, but not motility, compared with control ( Figure 4B ), suggesting that small RNA molecules induce chemotaxis of microglia, independent of their sequence. Pre-treatment of the oligoribonucleotides with RNase A abolished migration, confirming the specificity of microglial migration induced by ssRNAs ( Figure 4B ). To determine whether TLR7 is involved in microglial migration induced by small oligoribonucleotides, we performed agarose spot assay with microglia from Tlr7 À/À mice, using the same protocol previously used for WT microglia. TLR7-deficient microglia did not show increased migration when incubated with let-7b, let-7d, let-7e, or mutant oligoribonucleotides compared with control, implying that the migratory effect on microglia is dependent on TLR7 ( Figures 4A and 4B ). Taken together, incubation of microglia with let-7b, let-7d, and also let-7e led to increased migration. Our finding that a mutant control oligoribonucleotide lacking the Microglial migration in response to let-7b, let-7d, and let-7e oligoribonucleotides was analyzed by agarose spot assay. (A) Images of let-7b-treated and control microglial cultures from WT and Tlr7 À/À mice. Scale bar, 100 mm. (B) let-7b, let-7d, or let-7e (5 mg/mL) was added either to the spot alone (gradient/black) or both to the spot and the culture medium (no gradient/dark gray) with (light gray) or without RNase A pre-incubation. Microglial migration in response to 5 mg/mL let-7b, let-7d, or let-7e was also analyzed in Tlr7 À/À (white) microglia. PBS was used as negative control. Microglial migration was analyzed after 3 h of incubation. n = 8. Data are represented as mean ± SEM. *p < 0.05, **p < 0.01, and ***p < 0.001 versus control (one-way ANOVA followed by Bonferroni post hoc test).
GU-rich core motif also attracted microglia was unexpected and implies that, in contrast to the inflammatory response, microglial migration is modulated by small RNA in general but is not dependent on their sequence. Although we observed modulation of inflammatory response, antigen presentation, and migration by extracellularly delivered let-7 miRNAs, we did not observe any effect on microglial phagocytosis (unpublished data).
The selective modulation of microglial functions suggests that let-7, and perhaps other miRNA species, elicit a specific reprogramming of microglia that promotes some, but not all, physiological processes important for brain homeostasis. Still, the findings reported herein so far raise several important points regarding microglia function in the brain. First, microglial activation following let-7 exposure is a highly specific cellular response. It is not due to non-specific binding and/or the presence of contaminating factors. To this end, we used both a highly purified control mutant oligoribonucleotide, in which the GU content of the let-7 core motif was modified, and oligoribonucleotides, in which single nucleotides of the let-7 miRNA's sequence motifs were exchanged. Both control groups of oligoribonucleotides were handled and prepared identically to the respective let-7 miRNA tested, making it unlikely that the microglial response to the let-7 miRNA family was unspecific. TLR2-and TLR4-deficient but not TLR7-deficient microglia responded in a similar way to let-7 miRNAs as WT microglia, excluding the possibility that microglial activation after let-7 miRNA incubation was due to the presence of endotoxin or lipoproteins. These responses occurred independent of microglia developmental stage (Scheffel et al., 2012) , as neonatal and adult microglia behaved similarly. Finally, RNase treatment of let-7 miRNAs abolished microglial migration, confirming the RNA nature of the agents tested.
The Sequence Motif UUGU Is Required for let-7 miRNA-Induced Activation of TLR7 in Microglia let-7 miRNA family members exhibit different capacities to activate microglia, reflecting sequence specificity. The let-7 miRNA family is highly conserved between and within species, differing only in 1-4 nt among its members (Roush and Slack, 2008) . As such, let-7b possesses a sequence that contains the established TLR7 recognition motif GUUGUGU within its 3 0 terminus (Diebold et al., 2004; Heil et al., 2004; Lehmann et al., 2012a) . Other let-7 miRNAs such as let-7a, let-7c, let-7d, let-7e, let-7f, let-7g, let-7i , and miR-98 contain similar GU-rich motifs with minimal exchanges of nucleotides (Roush and Slack, 2008) . To determine the minimal motif within let-7 being necessary for microglial activation through TLR7, we used mutagenesis strategies, thereby analyzing the different let-7 miRNA family members (Table S1 ) with regard to their sequence-dependent potential to activate microglia. We observed that other family members besides let-7b, which lack this GUUGUGU motif, also activate microglia in a TLR7-dependent fashion. Specifically, the core motifs of let-7a, let-7c, let-7e, let-7f, and let-7g do not contain the last guanine and/or uridine. In addition, let-7f and let-7g do not possess guanine in the first position of the motif, and let-7d, which does not activate TLR7, contains a cytosine instead of the third uridine (Figure 5A) . As TLR7-dependent microglial activation was induced by let-7e but not let-7d, we hypothesized that the UUGU motif is responsible for microglial activation. To confirm this, we synthesized let-7d and let-7e mutant oligoribonucleotides: let-7d-mut-N (UUGC mutated to UUGU), let-7e-mut-N (UUGU mutated to AUGU), and let-7e-mut-CS (no mutation in the UUGU motif but upstream to this sequence) ( Figure 5B ). As expected, a point mutation in the let-7d core motif induced TLR7 activation and subsequent TNF-a release from microglia. In contrast, the point mutation in the let-7e core motif reduced TNF-a release. The mutation of six nucleotides at the 5 0 end of let-7e-mut-CS did not affect TNF-a levels compared with stimulation with the unmodified let-7e oligoribonucleotide, indicating that the presence of the UUGU core motif is sufficient for TLR7-dependent microglia activation ( Figure 5C ). In conclusion, these data imply that only the core sequence of four nucleotides, namely, UUGU, is required for let-7 miRNA-induced activation of microglia through TLR7. These findings are in accordance with those of previous studies that identified the sequence UUGU as minimum motif required for TLR7/TLR8-mediated cytokine responses mediated by human peripheral blood mononuclear cells (Forsbach et al., 2008) . This selectivity is important because it supports a model in which different let-7 miRNA family members have unique roles in modulating microglia function. Our finding that the UUGU sequence is required as a minimum core motif for let-7-induced microglial activation is relevant to our overall understanding of the specificity of the interactions between an extracellular miRNA and its cognate receptor, especially in the setting of brain disease (C) Supernatants from WT microglia stimulated with 5 mg/mL of unmodified let-7e and let-7d, as well as with 5 mg/mL of the mutated oligoribonucleotides let-7d-mut-N, let-7e-mut-N, and let-7-mut-CS, for 24 h were analyzed by TNF-a ELISA. n = 3. Data are represented as mean ± SEM. ***p < 0.001 mutated oligoribonucleotide versus respective naive oligoribonucleotide (one-way ANOVA followed by Bonferroni post hoc test). pathogenesis in which different let-7 molecules may be released. These findings provide potential new targets for therapeutic strategies, such as the development of inhibitor/agonist miRNAs as modulators of microglial activation in specific CNS disorders. let-7 miRNAs Are Differentially Expressed in Glioma and Induce TNF-a Release from Glioma-Associated Microglia and Macrophages On the basis of our previous studies on let-7b as a signaling molecule for neurons (Lehmann et al., 2012a) , we suggest that CNS cells, including immune cells, release let-7 miRNAs into the extracellular space, resulting in microglia activation. Whether cellular let-7 miRNAs passively leak into the extracellular space of the CNS or are actively secreted in their native state or enclosed in vesicles is unclear (Carlsbecker et al., 2010; Mittelbrunn et al., 2011) . It has been recently shown that lung tumor cells release miR-21 and miR-29a inside exosomes. These miRNAs are phagocytosed by macrophages and activate murine TLR7 and human TLR8 (Fabbri et al., 2012) . Whether this mechanism plays a role in let-7-mediated microglial activation remains to be elucidated. Our results extend the physiological role of let-7 miRNAs beyond their established role in regulation of gene expression to ligand-mediated activation of receptors in microglia. let-7 miRNAs function as signaling molecules in the brain, where they modulate CNS pathology and contribute to injury, tumor growth, and immune responses. It is well established that microglia/brain macrophages are highly abundant in brain tumor tissue, where they promote glioma growth (Hambardzumyan et al., 2016) . There are various cellular interactions between microglia/brain macrophages and glioma cells mediated by several signaling molecules, including osteopontin or versican (Hu et al., 2015; Szulzewsky et al., 2018) . Furthermore, let-7 miRNAs are differentially expressed in GBM and inhibit tumor growth by gene silencing (Degrauwe et al., 2016; Lee et al., 2011; Mao et al., 2013; Song et al., 2016; Wang et al., 2016) . Building upon our results, demonstrating that extracellular let-7 miRNAs function as signaling molecules for microglia and macrophages, we next sought to translate these findings to the setting of glioma. We comparatively assessed the expression levels of the let-7 miRNA family members in brain tissue derived from human glioma resection and in experimental mouse glioma models. Tumor samples from GBM patients, as well as tissue from the syngeneic GL261 and the induced RCAS/TV-a system mouse glioma models, were compared with control cortex tissue from patients with epilepsy and samples from healthy murine brain, respectively, using TaqMan PCR ( Figures 6A and 6B ). In human GBM samples, let-7b, let-7d, and let-7e expression levels were lower compared with control ( Figure 6A ). In glioma tissue derived from the murine GL261 model, let-7b expression was lower (Figure 6B;  for let-7b copy numbers, see Figure S5A ), while the other let-7 miRNAs showed no altered expression relative to control ( Figure 6B ). In glioma tissue from the murine RCAS model, let-7d and let-7e expression levels were lower compared with control ( Figure 6B ). let-7g and miR-98 miRNA expression levels were lower in human GBM tissue, whereas in the RCAS model, tissue let-7a, let-7c, let-7g, and miR-98 expression levels were lower relative to control ( Figure S5B ). In glioma tissue from the GL261 model, let-7c expression was lower, and let-7g expression was higher compared with control ( Figure S5B ). Expression levels of miR-21 and miR-210, two established glioma-associated miRNAs (Malzkorn et al., 2010) , were higher in human GBM and murine glioma tissue compared with control ( Figure S5B ). As noted above, we observed a TLR7-dependent induction of TNF-a from neonatal and adult microglia, as well as from macrophages, exposed to let-7. To determine how let-7 miRNAs affect the function of glioma-associated microglia and macrophages (GAMs), GL261-associated microglia and invading macrophages, as well as freshly isolated naive microglia, were incubated with let-7b, let-7d, or let-7e, and TNF-a levels were measured in the respective supernatants using and (B) tumor tissue from the murine glioma models GL261 or RCAS-hPDGFb and in healthy murine brain tissue. miR-16 was used as housekeeping control. n = 5 for human tissue samples, and n = 5-8 for mouse tissue samples of both glioma models. Data are represented as mean ± SEM. Human data were analyzed using the Mann-Whitney U test. Mouse data were analyzed using one-way ANOVA followed by Dunnett's post hoc test. *p < 0.05, **p < 0.01, and ***p < 0.001 versus control. (C) Freshly isolated naive microglia (black), GL261-derived glioma-associated microglia (dark gray), or glioma-associated macrophages (light gray) were stimulated with 5 mg/mL let-7b, let-7d, or let-7e for 24 h. LPS (100 ng/mL), LOX (1 mM), and mut. oligo (5 mg/mL) and LyoVec were used as positive and negative controls, respectively. TNF-a was detected using ELISA. n = 3-6. Data are represented as logarithm of mean ± SEM. The Kruskal-Wallis test followed by Dunn's post hoc test was used within each group. *p < 0.05, **p < 0.01, and ***p < 0.001 versus respective control condition. The Mann-Whitney U test was performed comparing GAMs versus naive microglia. # p < 0.05, ## p < 0.01, and ### p < 0.001 versus naive microglia. See also Figure S5 .
ELISA. Microglia and macrophages both expressing GFP and only macrophages expressing RFP were isolated from Cx3CR1-GFP x Ccr2-RFP mice using FACS ( Figure 6C ). Compared with controls, GAMs released TNF-a in response to let-7b or let-7e exposure. The extent of these responses were similar to those seen following LPS and LOX treatment. Naive microglia responded to let-7b and let-7e with TNF-a release similar to that observed in postnatal and adult microglia (see Figure 2) . Overall, the extent of TNF-a release from naive microglia in response to the let-7 miRNAs tested was lower than those induced in GAMs ( Figure 6C ). let-7d did not induce TNF-a release relative to control. As observed for let-7 miRNAs, levels of TNF-a induced by LPS and LOX in GAMs were also higher compared with those induced in naive microglia ( Figure 6C ). In summary, in human GBM and murine glioma, expression levels of a specific subset of let-7 miRNAs including let-7b and let-7e were lower relative to control. These let-7 miRNAs not only maintained their ability to activate microglia from glioma tissue but were even more potent inducers.
Extracellularly Delivered let-7b and let-7e Decrease GL261 Glioma Growth through TLR7 in Microglia Ex Vivo To assess the functional impact of let-7b, let-7e, and let-7d as signaling molecules on glioma growth, we used organotypic mouse brain slice cultures injected with mCherry-labeled GL261 glioma cells. In this experimental paradigm, let-7b, let-7d, or let-7e oligoribonucleotides were constantly present in the culture medium. Four days after tumor injection, tumor volume using three-dimensional (3D) surface reconstruction was determined ( Figure 7A ). let-7b and let-7e treatment resulted in reduced tumor volume compared with untreated slices. In contrast, let-7d treatment had no effect on tumor growth ( Figures  7A and 7B ). To investigate whether let-7 miRNA-mediated tumor reduction was dependent on TLR7, Tlr7 À/À brain slices injected with mCherry-GL261 tumor cells were also treated with extracellularly delivered let-7b, let-7d, or let-7e and analyzed as above. Tumors from Tlr7 À/À brain slices did not show any significant change in volume when treated with let-7b, let-7d, or let-7e relative to control ( Figure 7B ), indicating that TLR7 is required for the let-7b-and let-7e-mediated reduction of the tumor volume ex vivo. To assess whether microglia are required for let-7 miRNA-mediated tumor reduction, organotypic brain slices from WT mice were treated with clodronate-loaded liposomes for 24 h, followed 48 h later by the injection of glioma cells. As described previously (Markovic et al., 2005) , tumors in microglia-depleted slices were smaller relative to microglia-containing slices, and tumor growth was not affected following exposure to let-7b, let-7d, or let-7e relative to controls ( Figure 7B ), demonstrating that microglia account for tumor reduction induced by extracellular let-7b and let-7e.
To further investigate the effect of let-7 as a microglia signaling activator on glioma growth, we performed immunohistochemical analysis of the organotypic brain slices implanted with GL261 cells, as described above. Here, we focused on let-7b, the most prominent member of the let-7 miRNA family, which showed strong effects with respect to microglial activation and glioma growth inhibition. Glioma treated with extracellularly delivered let-7b revealed increased TUNEL-positive apoptosis and caspase-3 activation ( Figure 7C ). These effects were not observed in brain slices incubated with let-7d ( Figure 7C ), which did not activate microglia and did not affect GL261 tumor growth. We detected reduced cell viability ( Figure 7D ) and increased TUNEL-positive apoptosis and caspase-3 activation ( Figure 7E ) in GL261 cells following exposure to microglia-conditioned medium treated with extracellularly delivered let-7b. Again, this effect was sequence dependent, as let-7d did not induce such effects (Figures 7D and 7E) .
Although TLR7 is expressed in neurons and microglia, little or no TLR7 expression has been reported in astrocytes (Carpentier et al., 2005; Lehmann et al., 2012a; Olson and Miller, 2004) . To validate these findings, we measured TLR7 expression in microglia and astrocytes isolated from postnatal day (P) 14-and 12-week-old mice, as well as in GL261 and RCAS glioma cells, using qRT-PCR ( Figure S6 ). Microglia from both P14-and 12-week-old mice expressed high levels of TLR7, whereas neonatal astrocytes and adult astrocytes expressed no or only low levels of TLR7, respectively. In GL261-and RCAS-derived glioma cells, TLR7 expression was not detectable ( Figure S6 ).
In summary, our results imply a functional role for let-7 miRNAs as signaling molecules in glioma. Specific extracellularly delivered let-7 miRNAs not only mediate the interaction between microglia and glioma cells but also selectively suppress mouse glioma growth through microglial TLR7 signaling. Although we detected let-7b-mediated caspase-3-positive apoptosis in both the GL261 glioma model and in GL261 cells in vitro, the identification of the exact molecular mechanism responsible for the glioma reduction induced by extracellular let-7 miRNAs will require further investigation. It is tempting to speculate that select let-7 miRNAs serving as signaling molecules specifically reprogrammed microglial cytokine release, migration, and antigen presentation in a fashion that may have affected tumor growth. Moreover, let-7 miRNA family members act as chemoattractants for microglia and could increase microglia infiltration in glioma. In addition to the let-7 miRNAs' impact on tumor growth as TLR7 signaling activators, in their function as gene regulators on a posttranscriptional level they may directly target oncogene expression. Indeed, let-7 miRNAs have anti-tumorigenic effects in GBM cells by silencing stem cell programs, such as reducing RAS (Lee et al., 2011) or E2F2 (Song et al., 2016) expression. Thus, a greater understanding of the let-7 miRNAs' role in both direct microglia signaling and posttranscriptional changes may reveal potential roles for them as new therapeutic targets for GBM patients (Gilles and Slack, 2018) .
Conclusion let-7 miRNAs in their unconventional form as signaling molecules differentially induce microglial activation mediated by TLR7 in a sequence-dependent fashion, thereby modulating diverse functions of these cells, including inflammatory responses, migration, and antigen presentation. Translating these findings to a CNS disease context, we found that select let-7 miRNAs serving as signaling activators of microglia attenuate glioma growth. Future studies will be required to define the mechanisms underlying the Figure 7 . let-7b and let-7e Inhibit Glioma Growth through TLR7 and Microglia (A) Three-dimensional surface reconstruction of glioma tumors in organotypic brain slices from WT mice incubated with let-7b, let-7d, or let-7e for 4 days posttumor injection. Scale bar, 500 mm. (B) Quantification of tumor volumes in WT, Tlr7 À/À , and microglia-depleted WT organotypic brain slices treated with 5 mg/mL let-7b, let-7d, or let-7e. Data are represented as mean ± SEM. Brain slices from n = 4-8 biological replicates. *p < 0.05, **p < 0.01, and ***p < 0.001 versus control (one-way ANOVA followed by Bonferroni post hoc test). (C) Organotypic WT brain slices implanted with mCherry GL261 cells and incubated with let-7b or let-7d for 4 days were stained with TUNEL assay (upper image) and immunostained with activated caspase-3 antibody (lower image), as well as DAPI. Scale bar, 50 mm. Quantification of TUNEL-positive (upper graph) and activated caspase-3-positive (lower graph) cells. Data are represented as mean ± SEM. Brain slices from n = 4 biological replicates. *p < 0.05 versus control (oneway ANOVA followed by Bonferroni post hoc test). (D) Viability of GL261 tumor cells treated with let-7b-, let-7d-stimulated microglial conditioned medium (MCM) or control MCM for 24, 48, and 96 h. Data are represented as mean ± SEM; n = 4. *p < 0.05 and ***p < 0.001 versus control (one-way ANOVA followed by Bonferroni post hoc test). (E) GL261 cells were treated with let-7b-, let-7d-MCM or control MCM for 48 h. Cells were stained with TUNEL assay (upper image) and immunostained with activated caspase-3 antibody (lower image). Scale bar, 50 mm. Quantification of TUNEL-positive (upper graph) and activated caspase-3-positive (lower graph) cells. Unstimulated GL261 cells and control MCM were used as controls. Data are represented as mean ± SEM; n = 6 or 7. *p < 0.05 versus control (one-way ANOVA followed by Bonferroni post hoc test). n.s., not significant. See also Figure S6 . let-7 miRNAs' regulatory roles as signaling molecules in microglia in health and disease.
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STAR+METHODS KEY RESOURCES

Cell Lines
For fluorescence labeling, GL261 cells (Charles River Laboratory, Wilmington, MA, USA) were lentivirally transduced with a plasmid. Briefly, the mCherry gene was cloned into a lentiviral vector on a pRRL backbone (https://www.addgene.org/12252/), downstream of the MP71 promoter. After the production of viral particles, WT GL261 cells were transduced for 24 h at a MOI of 1 by using RPMI medium supplemented with 10% fetal calf serum, 2% Glutamin, 1% antibiotics Penicillin and Streptomycin, and 0.4 mg/ml Polybrene (Merck, Darmstadt, Germany). Transduction was stopped by adding new fresh medium. Mcherry-labeled GL261 cells (information on the sex of origin is unavailable) were selected via FACS cell sorting and frozen until further use.
Primary Cell Cultures
Neonatal primary microglial cultures from WT and TLR2-, TLR4-, and TLR7-deficient mice were prepared as previously described (Ifuku et al., 2016; Prinz et al., 1999) . Briefly, brains, including cortex and midbrain, from postnatal day 0-2 (P0-P2) male and female newborns were freed of blood vessels and meninges, mechanically dissociated into 1 mm 3 pieces and digested with 1% trypsin and 0.05% deoxyribonuclease. Digested tissue was further mechanically dissociated with a fire-polished pipette and washed twice in HBSS. Mixed glial cultures were plated and cultured for 9-12 d in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum and 1% antibiotics Penicillin and Streptomycin. After 7 d, 33% L292-conditioned medium was added to the cultures, and the microglial cells were isolated by gentle shaking at 37 C for 1 h on a shaker (100 rpm) and plated. Microglia from adult mice were prepared as described previously (Pannell et al., 2016) . In short, brains obtained from adult male mice (P49-56) were freed of blood vessels and meninges, mechanically dissociated, and digested with trypsin and DNase as described for neonatal cultures. After further dissociation cells were plated on a confluent monolayer of P0-P2 astrocytes in 75 cm 2 flasks. The feeder astrocytic layer was depleted of neonatal microglial cells by using chlodronate (200 mg/ml) before plating the microglial cells. Mixed adult and neonatal glial cultures were maintained in fresh complete DMEM, and the medium changed every third day, followed by addition of 33% L292-conditioned medium at day 7. One week later, cells were shaken off and used for experiments within 24-48 h.
Bone marrow-derived macrophages were isolated from WT male adult mice (P49-59) as previously described (Manzanero, 2012) . Mice were sacrificed by cervical dislocation, and their back legs were removed by cutting near the pelvic area. The skin was removed together with muscles, and ligaments, and the bone was cut below the ankle joint. The femur and tibia were isolated by slightly bending the knee joint. Complete RPMI 1640 tissue culture medium, supplemented with 10% heat-inactivated fetal bovine serum and 1% antibiotics, was flushed through the bone, and the contents collected into a sterile 15 mL polypropylene tube. After centrifugation for 5 min at 1200 rpm, red blood cells were lysed by adding Erylyse Buffer for 3 min and subsequently centrifuged for 5 min at 1200 rpm. Cells were then passed through a 70 mm cell strainer and plated in 10 cm dishes with fresh complete RPMI medium supplemented with 2 ng/ml of M-CSF to allow differentiation into macrophages. After 7 d, cells were trypsinized and used for experiments within 1 d of plating.
METHOD DETAILS
Isolation of Fresh Naive Adult Microglia and GAMs for Functional Assays
Microglia were isolated from healthy or GL261 tumor-bearing Cx3cr1 GFP/+ x Ccr2 RFP/+ male mice (P84). Mice were fully anaesthetized with Narcoren (Merial GmbH, Hallbergmoos, Germany) and transcardially perfused with ice-cold 1x Phosphate Buffered Saline (PBS). Brains were extracted, excluding the brain stem and cerebellum, and digested into a single cell suspension by using Adult Brain Dissociation Kit mouse and rat (Miltenyi Biotech GmbH, Bergisch Gladbach, Germany) according to the manufacturer's manual. Briefly, the kit consists of one enzymatic digestion step by using gentleMACS TM Dissociator with heaters followed by a debris and myelin removal step. Dissociated cells were directly isolated via Fluorescent-activated cell sorting (FACS) by using FACS Aria flow cytometer (BD Bioscences, San Jose, USA). The gating strategy used the GFP/RFP ratio from the reporter mice. Microglia, defined as the GFP high RFPpopulation, and invading macrophages, defined as the GFP high RFP + population, were sorted in fresh complete DMEM supplemented with antimycotics and antibiotics. Following centrifugation at 500 g for 5 min, 5x10 4 microglial cells were plated in a 96-well-plate, and used for experiments 24 hr later.
Microglia and astrocytes from P14 and 12-week-old WT male mice were isolated via FACS sorting by using the following dyecoupled antibodies: CD11b, CD45 (eBioscience, San Diego, USA), and ACSA2 (Miltenyi Biotech GmbH, Bergisch Gladbach, Germany).
let-7 miRNA Stimulation and TNF-a Enzyme-Linked Immunosorbent Assay
To test let-7 miRNA-mediated cell activation in vitro, we stimulated cells, collected the supernatant and tested for TNF-a release via an ELISA assay. Neonatal and adult primary microglia as well as bone marrow-derived macrophages were plated into a 96-well-plate at a density of 3x10 4 cells per well in 150 ml medium, while acutely isolated adult microglia were plated in a 96-well-plate at a density of 5x10 4 cells per well. To assess the time course, cells were stimulated with 660 nM of let-7 oligoribonucleotide for 9 h, 24 h and 30 h. To characterize the dose response, cells were stimulated for 24 h with increasing concentrations of the respective miRNA (1, 5 and 10 mg/ml corresponding to 132, 660, and 1320 nM, respectively). At the appropriate time point, supernatants were collected and tested for TNF-a concentration, expressed in ng/ml, using an enzyme immunosorbent assay (ELISA) and the mouse TNF alpha ELISA Ready-SET-Go! TM kit (Affymetrix eBioscence, San Diego, CA, USA) according to the manufacturer's manual. For treatment of GL261 cells with microglial conditioned medium (MCM), microglia were plated in a 6-well-plate at a density of 1x10 6 cells per well and stimulated with 5 mg/ml let-7b or let-7d oligoribonucleotide for 24 h.
Multiplex Immune Assay
Detection of cytokines in supernatants collected from microglial cell cultures stimulated over time with let-7 miRNA family members was performed using the ProcartPlex mouse Multiplex Immunoassay Mix&Match (Affymetrix eBioscience, Vienna, Austria) according to the manufacturer's manual. Briefly, the magnetic beads-based assay enables the simultaneous detection and quantification of multiple proteins in a single sample. Prior to incubation, samples were vortexed followed by centrifugation to remove particles. Detection of the proteins was performed by using Luminex 200. Analysis was performed by using Bioplex System Software 4.0 (Bio-Rad, Hercules, CA, USA). The cytokine analysis included TNF-a, IL-6, IL-10, IL-1b, GRO-a, MIP-2, RANTES, GM-CSF, IP-10, MCP-1, MCP-3, MIP-1a, and MIP-1b. Expression levels are shown as Mean Fluorescent Intensity (MFI).
Agarose Spot Assay
Agarose spot assay was performed as previously described (Wiggins and Rappoport, 2010) . In summary, 0.1 g of low-melting point agarose (Promega, Madison, WI, USA) was diluted in 20 mL of PBS originating 0.5% agarose solution. The solution was then heated until boiling and subsequently cooled down to 40 C. Afterward, 90 ml of agarose solution was mixed with 10 ml of PBS with or without let-7 miRNAs (at a concentration of 660 nM) in a 0.5 mL Eppendorf tube. 10 ml of mixed solution were rapidly plated into 35 mm glass bottomed dishes (Maktek Corporation, Ahland, MA, USA) and were cooled down for 10 min at 4 C. Four spots were pipetted in one dish, two containing PBS only and two with selected let-7 oligonucleotides. 5x10 5 microglia cells from WT or Tlr7 À/À mice were plated in the dish in 2 mL DMEM supplemented with 10% fetal calf serum and incubated at 37 C for 3 h. Subsequently, the cells inside the spot were counted under the microscope. To assess microglial motility, we also applied the respective oligoribonucleotide to the medium. For chemotaxis assays, let-7 oligoribonucleotides or mutant oligoribonucleotide, with or without RNase A (10 mg) pre-treatment, were only present inside the spot.
Flow Cytometry Analysis
Neonatal primary microglial cultures from WT and Tlr7 À/À mice were prepared as previously described (see above) and seeded at a confluency of 5x10 5 cells in a 35 mm Petri dish. Microglia were stimulated with let-7b, let-7d and let-7e (660 nM) for 24 h followed by cell collection by scratching in ice-cold PBS and centrifugation at 500 g for 5 min at 4 C. The cell pellet was resuspended in ice-cold FACS buffer (PBS supplemented with 1% fetal calf serum) and divided in two groups (each group contained 2x10 5 cells), for immunolabeling with the following dye-coupled monoclonal anti-mouse antibodies: CD45, CD11b, MHC I, MHC II and CD54 (eBioscience, San Diego, USA) for 20 min at 4 C. Next, cells were immediately acquired on a LSRII flow cytometer (BD Bioscience, San Jose, USA), and the data analyzed using FlowJo v10 software (Tree Star). Expression values are shown as MFI normalized to unstimulated control condition.
Tumor Injection In Vivo
Tumors were inoculated in vivo as previously described (Szulzewsky et al., 2015) . Injections were performed using a stereotactic frame (Stoelting, Wood Dale, IL, USA). Mice used for these experiments were 8-14-week old (C57BL/6 mice and Cx3cr1 GFP/+ x Ccr2 RFP/+ for GL261 cell injection, C57BL7/6 mice for RCAS-PDGFb tumor cell re-implantation) or 4.5-10-week-old (Ntv-a/Ink4a-Arf À/À mice for DF-1 RCAS-PDGFb injection). Mice were anaesthetized with intraperitoneal injections of ketamine (0.1 mg/g, Pharmazeutischen Handelsgesellschaft, Garbsen, Germany) and xylazine (0.02 mg/g, Bayer, Leverkusen, Germany). Animals were also treated with 0.25% Marcaine (volume about 0.1 ml/25 g) administered right before the surgery.
One microliter cell suspensions (2x10 4 GL261 cells, 4 3 10 4 transfected DF-1 cells, or 5x10 4 RCAS-PDGFb tumor cells) were delivered using a 30-gauge needle attached to a Hamilton syringe (Hamilton, Reno, NV, USA). Coordinates for GL261 injections into C57BL/6 mice were bregma 1 mm anterior, Lat (lateral) À2 mm (right of midline), and a depth À3 mm from the dural surface. Coordinates for injections of DF-1 cells and RCAS-PDGFb tumor cells into Ntv-a/Ink4a-Arf À/À mice and C57BL/6 mice, respectively, were bregma 1.5 mm anterior, Lat À0.5 mm, and a depth 2.0 mm. Mice were monitored daily for the first two weeks and twice a day starting from day 15 post-injection for symptoms of tumor development (lethargy, hydrocephalus, head tilting). At day 18-19 and day 30 for GL261 and RCAS, respectively, animals were sacrificed and perfused with 1x PBS followed by decapitation and brain resection.
Total RNA Extraction and Quantitative RT-PCR For let-7 expression analysis in human and murine brain samples, we extracted total RNA with the mirVana TM PARIS TM kit (Thermo Fisher Scientific, Waltham, MA, USA), according to the manufacturer's protocol. Briefly, human and murine brain samples were processed frozen and disrupted by using a mortar and pestle in a bed of dry ice. The tissue powder obtained was scraped and mixed rapidly into Cell Disruption Buffer. The mixture was then homogenized by using Ultra-Turraxâ (Merck, Darmstadt, Germany) at 21.500 rpm for 30 s. Once the lysate was homogenized, equal volume of 2x denaturating solution and incubated on ice for 5 min. Next, the sample lysate plus 2x denaturating solution was mixed with an equal volume of Acid-Phenol:Chloroform and vortexed for 60 s. After a centrifugation step of 5 min at maximum speed at room temperature, the upper aqueous phase was collected and transferred to a new tube. 1.25 volumes 100% ethanol were added to the aqueous phase, and the mixture was placed into the filtered column and centrifuged for 30 s at 10.000 g at room temperature. The column was then washed with miRNA Wash Solution 1 and 2/3 and ultimately eluted with RNase free water. Total RNA amount was quantified with the Thermo Scientific TM Nanodrop TM One spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA) . Reverse transcription and quantitative PCR was performed using the TaqManâ MicroRNA Assay, according to the manufacturer's manual. Taqman PCR reactions were performed in the Step one Plus Real Time PCR system (Applied Biosystems, Foster City, CA, USA). Expression data were normalized to miR-16 for each sample.
For detection of TLR7 expression in freshly isolated microglia, astrocytes, and the tumor cell lines GL261 and RCAS, cDNA was obtained using the SuperScript II reverse transcriptase (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. Quantitative real-time PCR was performed in a 7500 Fast Real-Time thermocycler (Applied Biosystems, Foster City, CA, USA) using SYBR select Master Mix (Applied Biosystems, Foster City, CA, USA). TATA-binding protein (TBP) was used as housekeeping gene. The following primers (synthesized by Biotez GmbH, Berlin, Germany) were used: mTLR7 forward 5 0 -ATGTGGACACGGAAGAGACAA-3 0 , mTLR7 reverse 5 0 -GGTAAGGGTAAGATT GGTGGTG-3 0 , TBP forward 5 0 -AAGGGAGAATCATGGACCAG-3 0 , TBP reverse 5 0 -CCGTAAGGCATCATTGGACT-3 0 .
Analysis of Cell Viability and Apoptosis in GL261 Cells
GL261 cells were treated with microglial conditioned medium (MCM) stimulated with select let-7 oligoribonucleotides, as indicated in the Figure legend, and cell viability and apoptosis rate were assessed. For viability assay, GL261 cells were plated in a 96-well-plate at a density of 1x10 4 cells/well and treated with 100 ml of let-7-stimulated MCM for 24, 48 and 96 h. At each time point, 10 ml of Cell Counting Kit-8 (CCK8, Tebu-Bio, Offenbach, Germany) reagent was added. After 2 h, absorbance was measured at 450 nm on a microplate reader (TECAN). Values were normalized to the unstimulated condition. For cell death analysis, GL261 cells were plated in a 24-well-plate at a density of 5x10 4 cells/well and treated with 300 ml of let-7-stimulated MCM for 48 h. Subsequently, cells were fixed in 4% PFA and analyzed by TUNEL assay and immunostaining employing an antibody against activated caspase-3 (see below).
Organotypic Brain Slice Cultures
Organotypic brain slice preparation was performed as previously described (Markovic et al., 2005) . Briefly, brains derived from P14-16 MacGreen animals were removed and placed in ice-cold PBS. Cerebellum and olfactory bulb were removed, and the forebrain was placed on a glass block and cut in the coronal plane into 250 mm sections with a vibratome (Microm HM650V, Thermo Scientific, Waltham, MA, USA). Brain slices were transferred onto 0.4 mm polycarbonate membranes in the upper chamber of a transwell tissue insert (Falcon model 3090, Becton Dickinson, Franklin Lakes, NJ, USA), which was inserted into a 6-well-plate (Falcon model 3502, Becton Dickinson, Franklin Lakes, NJ, USA) . To ensure the same experimental conditions three slices, representing three different brain areas, were mounted on each insert. Thereafter, brain slices were incubated in 1 mL of culture medium per well containing DMEM supplemented with 10% heat-inactivated fetal bovine serum (Atlanta Biological, Norcross, GA), 0.2 mM glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin (medium-1). After overnight equilibration of the brain slices in medium-1, slices were incubated with cultivation medium-2. Medium-2 contained 25% heat-inactivated horse serum, 50 mM sodium bicarbonate, 2% glutamine, 25% Hank's balanced salt solution, 1 mg/ml insulin, 5 mM Tris (all from Life Technologies, Carlsbad, CA, USA), 2.46 mg/ml glucose (Braun Melsungen, Germany), 0.8 mg/ml vitamin C, 100 U/ml penicillin and 100 mg/ml streptomycin (all from Sigma-Aldrich, St. Louis, MO, USA) in DMEM (GIBCO, Thermo Fisher Scientific, Waltham, MA, USA). Slices were maintained in culture for 5 d with medium change every two days.
Tumor Cell Injection into Brain Slices and let-7 miRNA Treatment One day after sectioning, 5000 cultured mCherry GL261 glioma cells in a volume of 0.1 ml were injected into the slices using a microsyringe mounted to a micromanipulator. An injection canal was formed that reached 150 mm deep into the 250-mm-thick slice. The needle was then retracted by 50 mm, leaving an injection cavity of approximately 50 mm where the tumor cell suspension was slowly inoculated over 30 s. Afterward, the syringe was pulled out in 10 mm incremental steps over 60 s. To ensure identical experimental conditions, gliomas were always inoculated in the striatal area of both hemispheres. In parallel to tumor inoculation, the let-7 miRNAs complexed with Lyovec were added to the medium at a concentration of 0,5 mg/ml and replenished when fresh new medium was changed so that the let-7 oligoribonucleotides were constantly present.
Depletion of Microglia
For microglial depletion, clodronate-loaded liposomes (Liposoma, Amsterdam, Netherlands) were used. Brain slices were incubated with the liposomes for 24 h at 37 C. Afterward, slices were incubated with medium-2 (see above) for equilibration, with glioma cell injections occurring at least two days later.
Immunofluorescence, Confocal Microscopy, and Tumor 3D Reconstruction GL261 cells seeded on coverslips and treated with let-7-stimulated MCM were fixed for 10 min in 4% PFA, washed 3x with PBS and incubated for 1 h at room temperature in permeabilization/blocking solution (5% normal donkey serum and 0.2% Triton X-100 D-PBS). Subsequently, anti-rabbit activated caspase-3 antibody was added to the permeabilization/blocking solution (1:300), and cells were incubated at 4 C overnight. This step was followed by adding DAPI solution (1:5000; Sigma-Aldrich, St. Louis, MO, USA) and donkey anti-rabbit Alexa Fluor 647 (1:500) incubation at room temperature. Afterward, coverslips were mounted and analyzed at the confocal microscope. For TUNEL analysis, In Situ Cell Death Detection Kit, Fluorescein (Roche, Basel, Switzerland) was used, according to the manufacturer's manual. Briefly, cells were permeabilized and blocked in a D-PBS solution containing 0.1% sodium citrate and 0.1% Triton X-100 for 3 min on ice. Afterward, cells were incubated with the TUNEL reaction mixture for 1 h at 37 C, followed by 3x washing with D-PBS, and incubation with DAPI solution, before mounting on a glass slide.
Organotypic brain slices were fixed at day 4 post-injection with 4% PFA for 1 h followed by PBS washing and incubation overnight at 4 C with D-PBS supplemented with 5% donkey serum and 0.3% Triton X-100. Slices were incubated with anti-rabbit activated caspase-3 primary antibody (1:100) for 24 h followed by 3x washing with D-PBS. Incubation with donkey anti-rabbit Alexa Fluor 647 secondary antibody (1:250) was performed for 2 h at room temperature. In addition, staining with DAPI was performed for 2 h. For TUNEL staining, ApopTag Plus Fluorescein In Situ Apoptosis Detection Kit (Merck, Darmstadt, Germany) was used following the manufacturer's instructions. Briefly, after 1 h fixation in 4% PFA, slices were incubated for 10 min at room temperature with permeabilization buffer containing ethanol: acetic acid, 2:1 (v:v). Slices were incubated for 1 min with equilibration buffer and subsequently incubated with the TUNEL reaction mixture (TdT enzyme and reaction buffer) for 2 h at 37 C in a humidified chamber. The reaction was stopped by incubating the slices with the stop/wash buffer for 15 min at room temperature. Finally, anti-digoxigenin-conjugated solution was applied on the slices for 30 min at room temperature. Slices were mounted for tumor volume quantification and apoptosis analysis. Tumor volumes were determined by using the confocal laser microscopy scanning (Leica TCS SPE, Leica Microsystems, Wetzlar, Germany). We acquired images with a 20x oil immersion objective by using a z stack with a 2 mm step size interval and tile scan mode. Data analysis to assess tumor volume was performed by using Imaris 9 (Bitplane, Z€ urich, Switzerland). Tumor volumes of high-resolution SPE confocal microscopy stacks were 3D rendered by application of 1 mm object detail, 15 threshold background and 1000 tridimensional pixels (voxels). The surface objects obtained were unified in one single object, and volume mean values were extracted.
For apoptosis quantification in vitro and ex vivo, we acquired 4 images per coverslip/tumor at 20x and quantified by ImageJ software with the additional threshold adjustment tool and cell counter plug in.
QUANTIFICATION AND STATISTICAL ANALYSIS
All experiments were performed at least three times, and all data were represented as mean ± SEM. We assessed statistical significance by using Prism 7 Windows (GraphPad Software, San Diego, CA, USA). For ELISA and multiplex analysis we used Kruskal-Wallis test followed by Dunn's multiple comparison post hoc test. For migration studies, FACS analysis, viability/cell death analysis, and comparison between organotypic brain slices, one way ANOVA followed by Bonferroni post hoc test, was performed. For paired comparison in human and mouse quantitative PCR analysis, Mann Whitney U test or one way ANOVA followed by Dunnett's multiple comparison post hoc test was performed. Significance was set at p < 0.05. Primary cultured bone marrow-derived macrophages from WT mice were stimulated with 5 µg/ml let-7a-let-7i or miR-98 oligoribonucleotides for 9, 24, or 30 h. LPS (100 ng/ml) and LOX (1 mM) and mutant oligoribonucleotide (mut. oligo; 5 µg/ml) and LyoVec were used as positive and negative controls, respectively. n = 4. Data are represented as mean ± SEM.
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